title: Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
abstract: OBJECTIVE
  To evaluate the subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in patients with retinal angiomatous proliferation.
  
  
  METHODS
  Subfoveal choroidal thickness was retrospectively measured using enhanced depth imaging optical coherence tomography.
  
  
  RESULTS
  Thirty-two eyes of 26 patients (average age, 82 years) with newly diagnosed retinal angiomatous proliferation were examined. All eyes were treated with intravitreal ranibizumab and photodynamic therapy. In 14 eyes without recurrence over 6-month follow-up (average, 8.4 months), mean subfoveal choroidal thickness decreased from 198 μm at baseline to 169 μm (85.4%) at 3 months and to 173 μm (87.3%) at 6 months after treatment (P < 0.01 compared with baseline, respectively). In 18 eyes with recurrence over 3-month follow-up, mean subfoveal choroidal thickness decreased from 199 μm at baseline to 171 μm (85.9%) at 3 months after treatment and 176 μm (88.4%) even at recurrence (P < 0.01 compared with baseline, respectively).
  
  
  CONCLUSIONS
  Subfoveal choroidal thickness after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation decreased to approximately 85% compared with baseline by 3 months after treatment, and the trend persisted in eyes with or without recurrence during follow-up. This may indicate that choroidal changes are not associated with recurrence in retinal angiomatous proliferation.
authors: *Department of Ophthalmology, School of Medicine, Fukushima Medical University, Fukushima, Japan; and †Department of Ophthalmology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
authors: Ichiro
authors: I
authors: Maruko
authors: Tomohiro
authors: T
authors: Iida
authors: Hiroshi
authors: H
authors: Oyamada
authors: Yukinori
authors: Y
authors: Sugano
authors: Masaaki
authors: M
authors: Saito
authors: Tetsuju
authors: T
authors: Sekiryu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002829:Choroid / Q000473:pathology*; D004396:Coloring Agents; D003131:Combined Modality Therapy; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D010778:Photochemotherapy; D000069579:Ranibizumab; D012160:Retina / Q000473:pathology; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D007208:Indocyanine Green; D000069579:Ranibizumab